CP
ACAD icon

CenterBook Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

CenterBook Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$439K Buy
+19,736
New +$472K 0.02% 510
2025
Q4 		– Sell
-11,152
Closed -$238K – 543
2025
Q3 		$238K Buy
+11,152
New +$264K 0.01% 533

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

CenterBook Partners's ACAD Position: Q1 2026 in Review

CenterBook Partners opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 19,736 shares worth $439K. The stake represents 0.02% of the portfolio and ranks #510 among its holdings. This is a return to the name: CenterBook Partners previously reported a position in ACAD as recently as Q3 2025.

CenterBook Partners first reported a position in ACAD in Q3 2025 and has held it in 2 quarters since. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • CenterBook Partners held 19,736 shares of Acadia Pharmaceuticals worth $439K as of Q1 2026.
  • Acadia Pharmaceuticals was a new CenterBook Partners position in Q1 2026.
  • Acadia Pharmaceuticals made up 0.02% of CenterBook Partners's portfolio in Q1 2026, its #510 holding.
  • CenterBook Partners first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on CenterBook Partners's 13F filing for Q1 2026, filed 5 May 2026.